Shots:

• Cyclica to receive up front- milestones upon completion of specific stages for Project Nexus. AUM to get right to develop & commercialize therapies resulting from Project Nexus
• The collaboration leverages AUM’s drug development expertise including its biomarker-driven approach with Cyclica’s AI-augmented and structure-based platform- Ligand Design and Ligand Express
• The companies will design molecules with greater precision and speed- minimizing unwanted off-target effects while providing an understanding of their activity via systems biology and structural pharmacogenomics- addressing the unmet medical needs of patients in Asia

Click here ­to­ read full press release/ article | Ref: Business wire | Image: AUM Bioscience